This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 24, 2013 /PRNewswire/ -- Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by
Candida) in non-pregnant women
1, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country.
Ther-Rx has partnered with Perrigo (
www.perrigo.com) to manufacture Gynazole-1. Perrigo is a leading manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1.
"We are pleased to be able to once again offer Gynazole-1 to prescribing healthcare providers and to patients in need of therapy," said
Greg Divis, President of Ther-Rx and CEO of K-V Pharmaceutical Company. "The availability of Gynazole-1 represents a positive step forward for the Company as we continue to provide quality, patient-friendly products to support the health of women across the stages of their lives."
Yeast infections (VVC) are very common in women.
The 2010 Centers for Disease Control and Prevention (CDC) guidelines state that an estimated 75% of women will have at least one episode of VVC, and 40%–45% will have two or more episodes of VVC, within their lifetimes.
2 Gynazole-1, the only one-dose, anytime prescription cream for the treatment of vaginal yeast infections caused by all Candida species in non-pregnant women, is on the CDC recommended list.
"Women experiencing vaginal infections are eager for treatments that provide fast initial relief from symptoms and convenience in dosing and administration," said
David Gandell, MD, Clinical Professor of Obstetrics and Gynecology,
University of Rochester School of Medicine and Dentistry. "Gynazole-1 is a well-established treatment option, so it's great to be able to prescribe it for my patients again."
For more information about Gynazole-1, visit
www.gynazole-1.com or call Ther-Rx customer service at (877) 567-7676.
Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%) is indicated for the local treatment of vulvovaginal candidiasis (infections caused by
Candida). The diagnosis should be confirmed by KOH smears and/or cultures.
Note: Gynazole-1 is safe and effective in nonpregnant women; however, the safety and effectiveness of this product in pregnant women has not been established.